Q4 2025 Abcellera Biologics Inc Earnings Call Transcript
Key Points
- AbCellera Biologics Inc (ABCL) successfully transitioned to a clinical-stage biotech, completing key objectives such as initiating Phase 1 trials and nominating two new development candidates.
- The company ended 2025 with approximately $700 million in available liquidity, providing a strong financial position to support ongoing and future projects.
- ABCL's lead program, ABCL635, advanced into a Phase 2 study, with promising target engagement data that increased the estimated probability of success.
- The company has a growing pipeline with multiple first-in-class programs and expects significant clinical readouts and potential catalysts in 2026 and 2027.
- ABCL's clinical manufacturing facility is substantially complete, allowing for better control over the supply chain and intellectual property protection.
- ABCL reported a net loss of approximately $146 million for the year, reflecting ongoing investments in internal programs.
- Revenue for 2025 was $75 million, which, although an increase from 2024, still reflects the company's focus on internal pipeline development over partner-initiated programs.
- Research and development expenses increased to $187 million, indicating higher costs associated with advancing internal programs.
- The company anticipates potential delays in progressing to a late-stage clinical company if the Phase 2 readout of ABCL635 is negative.
- ABCL plans to stop reporting on partner-initiated program starts on a quarterly basis, which may reduce transparency for investors interested in these collaborations.
Good afternoon, and welcome to AbCellera's full-year 2025 fusiness update conference call. My name is Chelsea, and I will facilitate the audio portion of today's interactive broadcast. After today's prepared remarks, we will host a question-and-answer session. (Operator Instructions)
At this time, I would like to turn the call over to Tryn Stimart, AbCellera's Chief Legal and Compliance Officer. You may proceed.
Thank you. Hello, everyone, and thank you for joining us today for AbCellera's Full Year 2025 Earnings Call. I'm Tryn Stimart, AbCellera's Chief Legal and Compliance Officer. Dr. Carl Hansen, AbCellera's President and CEO; and Andrew Booth, AbCellra's Chief Financial Officer, will be speaking on today's call. Also, Sarah Noonberg, our Chief Medical Officer, is on the call with us.
During this call, we may make projections and forward-looking statements based on current expectations and in accordance with the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
